American Shared Hospital Services (AMS) Earnings Call Transcript & Summary
November 10, 2022
Earnings Call Speaker Segments
Stephanie Prince
executiveThank you, Matt, and I'm glad every one of you could join us today. Before trading began this morning, AMS released its earnings press release covering the third quarter of 2022. If you need a copy, it's available on the company's website, ashs.com, under Press Releases in the Investors tab. Before I turn the call over to management, I want to make a few remarks about forward-looking statements. Please note that various comments made during this conference call about future expectations, plans and prospects for the company count as forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. There's a chance our actual outcomes could differ significantly from what those forward-looking statements suggest, due to a range of significant factors — among them the ones covered in the documents the company has filed with the SEC. Those documents include our quarterly reports on Form 10-Q covering the 3-month periods that concluded on March 31, 2022, and June 30, 2022, along with the annual report on Form 10-K for the year that ended December 31, 2021, plus the definitive proxy statement tied to the Annual Meeting of Shareholders held on June 21, 2022. Nothing obligates the company to refresh any of the information shared in this conference call. With that said, I'd now like to turn things over to Ray Stachowiak, who serves as CEO of AMS. Ray?
Ray Stachowiak
executiveThanks, Stephanie, and hello to everyone this afternoon. We appreciate you being with us for the earnings conference call covering the third quarter of 2022. I'll make a few opening comments first. After that, I'll hand things to Craig Tagawa, who serves as our President and CFO, to walk through the financials for the third quarter. Craig will then pass the call to Peter Gaccione, who was recently named Chief Operating Officer of AMS. Peter will take a few minutes to discuss what his initial priorities are and his plans for sales and operations. Once those prepared remarks are finished, we'll take your questions. For AMS, the third quarter was yet another solid one. Revenue rose 18%, powered by greater PBRT volume along with increased average reimbursement for Gamma Knife procedures and proton beams alike; across the first 9 months of the year, revenue was up 14%. Net income came in at $316,000 for the third quarter, equal to $0.05 per diluted share — marking the fifth quarter in a row that we've posted positive earnings. Measured on a trailing 12-month basis, earnings per share have reached $0.21 in total. Our cash has also increased during that period and stands at $11.7 million now, amounting to $1.90 for each outstanding share when the quarter closed. Craig will share more specifics shortly, but I take pride in what we've accomplished and in everything our team has done across the past couple of years. As we've discussed, that includes bolstering the balance sheet so we can take on new projects, broadening what we offer in products and services and, most recently, adding seasoned sales and operations leadership to bring in new business. We were pleased to name Peter Gaccione Chief Operating Officer back in September. Within the healthcare industry, Peter is widely known and highly regarded, and he brings deep market expertise spanning the full radiation oncology spectrum. Our company has been familiar with him for many years. Peter possesses the right background and professional connections, and we're confident he's the right individual to head the company's operating efforts. Peter will be collaborating with Tim Keel, a senior healthcare finance professional who came aboard last May as our Vice President of Sales and Marketing, and Ernie Bates, Vice President of International Sales and Marketing, who has spent many years with the company; with this team now assembled, we're eager to put our very strong financial resources to work — the $11 million in cash plus our unused $7 million line of credit — as we aggressively chase new business opportunities for our company. I'll now hand the call to Craig for his third quarter financial review. Craig?
Craig Tagawa
executiveThanks, Ray, and good afternoon to all of you. Revenue for the third quarter rose 17.6%, reaching $4.8 million, up from $4.1 million during the same quarter a year ago. For a number of quarters now, we have reported improving revenue since hitting pandemic lows. Revenue grew 14% across the first 9 months of the year. In Florida, third quarter revenue for the proton therapy system climbed 82.4% to $2.4 million, helped by ongoing volume growth and better average reimbursement during the quarter. Total proton therapy fractions for the third quarter rose 40.1%, hitting 1,363 versus 973 in last year's third quarter. The COVID-19 pandemic affected last year's quarter, along with downtime tied to certain system repairs. Gamma Knife revenue fell 12% to $2.5 million relative to Q3 of last year. That decline stemmed from fewer procedures, partly offset by higher average reimbursement, which itself resulted from a rise in the average rate at the company's retail sites, brought about by a favorable payer mix shift toward more commercial payers. Revenue for same centers in operation, which leaves out the 2 Gamma Knife contracts that expired, 1 each in the first and fourth quarters of 2021, dropped 12.5% versus those same centers during the comparable period a year earlier. Gamma Knife procedures declined by 12.8% to 293 in the third quarter, mainly because of the expiration of those 2 contracts I just referenced. For same centers in operation, Gamma Knife volumes across the 3- and 9-month periods fell 9.3% and 4.4%, respectively, compared with Gamma Knife volumes at those same centers during the equivalent period the year before. During the current period, several of our domestic customers experienced temporary staffing shortages, on top of normal cyclical fluctuations. We went back and compared our present Gamma Knife volumes with 2019, the year preceding the pandemic, and same-store volumes are higher for both the third quarter and 9-month periods versus that time. At our international locations, volumes at our center in Ecuador have improved. The Icon upgrade at that center is now set for spring 2023, with the delay tied to securing the required regulatory approvals. It will rank among the few Gamma Knife Icon units anywhere in South America. The new linear accelerator for our joint venture in Puebla, Mexico is now set for spring 2023 as well. Again, this depends on the required licensing and regulatory approvals. Gross margin dollars rose 33.4% to $2 million in the third quarter. The gross margin percentage widened 470 basis points to 40.5% of revenue. That gain came despite higher operating costs at the company's international sites, driven by increased volumes. Selling and administrative costs rose by 12.6% to $1.3 million in the third quarter, due to higher sales and related fees tied to new business opportunities. Operating income rose 141% to approximately $0.5 million, reflecting higher revenue and cost — good cost container. For the 3-month period, income tax expense rose to $176,000, versus $17,000 during the comparable stretch a year earlier. Higher earnings in the current period drove that rise in income tax expense, along with return to provision adjustments stemming from foreign income tax returns filed this period, plus permanent domestic tax differences that should persist through the close of this year. Net income attributable to American Shared Hospital Services came in at $316,000, or $0.05 per diluted share, for the third quarter of 2022, against net income of $33,000, or $0.01 per diluted share, for the third quarter of 2021. Fully diluted weighted average common shares outstanding moved up slightly from last year, reaching 6,273,000. Adjusted EBITDA, which is a non-GAAP financial measure, climbed 28% year-over-year, hitting $1,999,000 in the third quarter of 2022. As of September 30, 2022, cash, cash equivalents and restricted cash totaled $11,664,000, compared with $8,263,000 as of December 31, 2021. Shareholders' equity, excluding noncontrolling interest in subsidiaries, stood at $21,215,000, or $3.45 per outstanding share, on September 30, 2022, versus $19,893,000, or $3.28 per outstanding share, on December 31, 2021. To wrap up, we feel AMS has grown stronger across the board and is set for renewed growth in the years to come. I'll hand the call to Peter now so he can share a few remarks regarding his mandate and where he'll focus first. Peter?
Peter Gaccione
executiveCraig, thanks for that, and hello everybody on this afternoon's call. It's a pleasure to be with you, and I see real promise in what lies ahead for AMS. Within radiation oncology, and this sets AMS apart, cancer treatment clinics can work with every one of the big original equipment manufacturers by way of a single turnkey supplier inside a single innovative partnership. That kind of arrangement is rare in our field, and it ranked among the biggest reasons I chose to come on board with the AMS leadership group. Over the handful of weeks since I came aboard, my attention has gone to a few carefully chosen priorities. Number one, I've been pushing hard alongside the leading OEMs to reinforce our commercial ties and to build combined sales and marketing playbooks. Those playbooks aim at winning new sockets with sophisticated treatment platforms and offerings built around linear accelerators, MR/LINAC, proton beam therapy, plus full turnkey offerings like new vaults, room renovations and even modular buildings. Number two, I've been engaging our customers and our existing installed base at Lexel Gamma Knife locations and treatment centers in order to reinforce and deepen those commercial ties. A lot of the sites we've installed are now at a point where planning has to begin — whether for upgrades, for fresh systems that swap out what they run today, or even for looking into widening what their current centers can treat by bringing in additional products that help cancer patients; keeping these relationships solid matters enormously when it comes to overseeing and extending the life cycle of what we've installed. A third priority for me has been creating and rolling out fresh sales and marketing tactics and programs that support our sales organizations with lead generation, prospecting, managing the funnel — the sales funnel — and the pipeline. A few of those tactics involve collaborating more closely with the sales and marketing groups at the leading OEMs, and also at their senior leadership tier, meaning we bring senior management together with the OEMs. On top of that, we intend to lean on more precisely targeted sales and marketing data revealing where the greatest incidence of cancer treatment occurs, then raise that point with prospects through a more consultative style of selling. Beyond that, and tied into this, we'll be partnering more closely with a specialist marketing firm so we can help customers promote their treatment capabilities to cancer patients in their own communities, to local physicians and hospitals, and to cancer survivors too. That way, whenever someone has to suggest a treatment facility to a relative or a friend, they'll know which one offers the newest treatments on the market; those are merely a handful of the priority areas I've tackled since arriving in September; and naturally, plenty of other areas will get attention down the road. I'm very eager to bring you up to date on how we're doing in the coming quarters. Thanks for tuning in today; that wraps up the formal portion of what we're presenting.
Tony Kamin
analystFrom what I can see, and having held AMS shares on and off for roughly two decades, I'd say this was among the strongest quarters — possibly the strongest — that I've witnessed. So well done on that. Still, I'm wondering about Gamma Knife volumes, which you said were lower because of factors such as short-term staffing problems; during the current quarter, are you beginning to observe that sort of activity returning to normal?
Ray Stachowiak
executiveI appreciate the question. As you're aware, we're unable to discuss what happened in the fourth quarter on this call, but we're tracking very carefully what's behind the declines in our Gamma Knife volumes. We've experienced certain staffing shortages, and we'd be glad to offer perhaps a few illustrations that Craig can walk through, and to reassure you that this is something we're fully aware of and that management is pursuing corrective measures. Craig, could you provide Tony, along with the other investors joining us, with a few illustrations?
Craig Tagawa
executiveAbsolutely. Tony, as you're aware, a major feature of the agreements we hold is the absence of any guaranteed minimum volumes. That means when staffing shifts occur at certain centers — which is what happened during the third quarter, as we noted in the press release — we can see short-term declines. In one instance, a treating physician departed from one location, though that doctor has returned since. That accounted for one of the drops, a sizable decline at a particular center of ours. Then there was a separate situation involving inadequate staffing. As you're aware, staffing shortages are widespread across healthcare right now, and we ran into that as well; it has since been resolved. Those represent 2 cases in which we took a hit across the 9-month period, and especially during this year's third quarter.
Tony Kamin
analystAll right. And the way you described all the new or expanded initiatives you're undertaking — like building tighter connections with your manufacturers, plus the sales teams and the manufacturers — that sounds very encouraging. Looking at the — just the outstanding results from your existing proton beam, I realize I've raised this before, but it seems as though that would be a fantastic reference customer for hospitals, really showing them the tangible benefits of the favorable economics they could get. I understand that's weighed against the current economic climate with considerably higher interest rates, which isn't a good thing, but could you discuss proton beam specifically? And what it might take to reach some sort of breakthrough there, where you could begin actually placing some of these?
Ray Stachowiak
executiveYes. Tony, excellent question; we operate 1 proton beam center in Orlando, as you know well. It's doing well. For years now, we've been attempting to develop additional proton beam centers. And we keep at it, and our efforts in that direction are likely stronger at present than they've ever been, mainly since we have more human resources dedicated to chasing that business. We have Peter. We have Tim Keel. We brought in myself a couple of years ago, along with Craig and Ernie Bates, Junior. So we have additional resources on that; but we won't sit idle waiting to secure our second, third proton beam deal. We believe that will come eventually. But for now, let's broaden our product offerings. There's enormous demand and need for radiation oncology equipment. And it doesn't have to be only protons. It doesn't have to be Gamma Knife either. So we've somewhat broadened our product offerings so we can grow our business and avoid depending on any 1 product or manufacturer. Those proton beam opportunities, I'm confident they'll arrive in due course. And we won't hesitate to chase that at all. We'll chase it aggressively. And I believe our day will arrive when that second and third systems get placed.
Tony Kamin
analystAll right, and I want to say that I truly appreciate and strongly back what you're doing by bringing in additional new equipment, expanding AMS' offerings, and possibly introducing some items there that cost a bit less and are simpler to secure approval for placing in hospitals. As a closing thought, Ray, specifically, even though market drops have made many stocks genuinely inexpensive, when I examine AMS using any kind of quantitative lens, the company's valuation still appears astonishingly low to me. So I'm just curious whether you have any views about what could be done to tackle that issue?
Ray Stachowiak
executiveWell, Tony, my agreement with you couldn't be stronger. I completely concur, and we'll share these remarks with our investors during this call, that in our view our stock is undervalued. I said as much — I gave a talk at the LD Micro conference a couple of weeks back out in L.A. and expressed the very same point. I'm pleased to report that when you look at our trailing 12 months of earnings, our EPS across that period comes to $0.21 per share. What we closed at yesterday was $2.73. That works out to a P/E ratio of 13%. In my view, that's a fairly low PE ratio, and with nearly every quarter that passes, that PE ratio keeps dropping further and further, so I believe we're undervalued; and being bullish about our company and our stock is part of what I'm supposed to do. That's one factor behind why I've become our biggest shareholder, now owning close to 18%, 19%, 20%. I stay very bullish. We aren't widely followed. I'll admit that a year or 2 back I was hesitant to go on the road and promote our stock. In my view, we had to resolve some internal issues we were facing and strengthen the foundation of our company, and I believe that's now been accomplished. So at this point let's grow our sales and management, marketing efforts, operations management, and let's find out how we can expand our company. I'd also like to mention that if you annualize our first 9 months of this year, we come in near roughly $19.5 million, $20 million on an annualized basis for 2022. We finished last year at approximately $17.6 million of rev. So even without adding incremental new revenue streams, we've expanded our business by double digits. That's a solid achievement. And it shows our efforts to boost volumes from our own existing sites, which, given our high fixed cost structure, really contributes to the bottom line whenever we raise their treatment volumes.
Tony Kamin
analystAnd honestly, when you evaluate this business the way I do — through an EBITDA lens — the valuation looks even more striking. Regardless, I truly appreciate all the questions, and best of luck moving ahead. Thanks so much.
Ray Stachowiak
executiveThank you, Matt, and thanks to each of you who took the time to be with us today. In wrapping up, I'd like to reiterate the point I raised regarding our earnings per share of $0.21. With yesterday's closing price of $2.73 and a PE ratio of 13, that strikes me as a modest valuation. We have a solid base beneath us. We also have considerable capital at our disposal for investment — capital that's ready to deploy. We've grown our sales, management, and marketing team. And I genuinely feel we're set up nicely to pursue what I've consistently described as our objective: sustained growth and profitability. So, having said all that, thanks once more; we can't wait to talk with you again on our fourth quarter and year-end call in early March. Should you have any questions, don't hesitate to reach out to us directly. We value your time — take care, stay safe, and goodbye.
Operator
operatorThat brings today's presentation to a close. We appreciate everyone joining us. You're welcome to leave the call at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →For developers and AI pipelines
Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.